Fine-tuned model from the PsyNamic project.
Superseded. This is the model of the initial PsyNamic submission (tag
submission-v1). It was replaced after retraining under a corrected protocol (Nov 2026) by STRIDE-lab/scibert-clinical-trial-phase-20261106. All current models: PsyNamic collection.
emilyalsentzer/Bio_ClinicalBERT
Clinical Trial Phase (multi-label: several labels per abstract possible)
Identifies the trial phase (I-IV) or whether it is non-applicable.
| ID | Label | Definition |
|---|---|---|
| 0 | Phase 1 | Tests safety, dosage range, and pharmacokinetics in 20–100 people (usually healthy) |
| 1 | Phase 2 | Tests effectiveness and optimal dosing; 100–300 patients; often randomized and single- or double-blind. |
| 2 | Phase 3 | Large-scale testing (hundreds–thousands) to confirm safety and effectiveness before approval, randomized and double-blind |
| 3 | Phase 4 | Post-marketing surveillance; monitors long-term safety, rare side effects, and real-world effectiveness. |
| 4 | Unknown | Fulfilling above definition but phase not explicitly (or implicitly) mentioned |
| 5 | Not Applicable | Not fulfilling the above definition, e.g., an fMRI study assessing the changes upon lsd or a survey among MDMA users or a systematic review. |
{
"mode": "train",
"data": "<private_dataset>",
"task": "Clinical Trial Phase",
"model": "clinicalbert",
"cross_val": false,
"batch_size": 8,
"learning_rate": 5e-05,
"weight_decay": 0.01,
"lr_scheduler": "linear",
"warmup_ratio": 0.1,
"epochs": 30,
"dropout": 0.1,
"early_stopping_patience": 5,
"gradient_clipping": 0.1,
"device": "cuda",
"load": null,
"max_length": 512,
"is_multilabel": true
}
emilyalsentzer/Bio_ClinicalBERT